



Mental and Behavioral Health Disorders (MBHD) Among Patients with Metastatic and Non-Metastatic Cancer: A Claims-Based Analysis

Ali Tafazzoli¹, Yi Zhang², Yen-Hua Chen², Anuraag Kansal¹

¹ GRAIL, Inc., Menlo Park, CA, United States; ² KMK Consulting, Morristown, NJ, United States

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025
November 9-12, 2025, Glasgow, Scotland

INTRODUCTION

- Cancer diagnosis and treatment often bring a substantial burden on patients, significantly diminishing their overall well-being and quality of life.
- The mental component of this burden can present as mental and behavioral health disorders (MBHD) such as anxiety, depression, stress, substance abuse, and somatoform disorders¹.
- MBHD in cancer patients are often linked to poorer treatment adherence, higher acute-care utilization, and worse survival²⁻³.

OBJECTIVE

- This study explores the prevalence of first-onset and recurrent MBHD in patients with metastatic vs non-metastatic cancers.

KEY RESULTS: PATIENTS WITH METASTATIC CANCER HAVE A HIGHER RISK OF FIRST-ONSET MBHD THAN THOSE WITH NON-METASTATIC DISEASE

RESULTS

- Figure 1 shows Sankey diagrams of MBHD status changes from pre-diagnosis (Yes/No) to post-diagnosis (No, first-onset, new recurrent, existing recurrent) for non-metastatic and metastatic cancers by age group.
 - First-onset prevalence was higher in metastatic vs non-metastatic patients; 17.3% vs 10.6% in 50–64 age group and 14.4% vs 9.4% in 65+ age group.
 - Roughly 9% showed MBHD before cancer yet no MBHD claims afterward, consistent in both metastatic and non-metastatic cohorts and across both age groups.
- Men had a higher percentage of first-onset MBHD than women in both age groups (Fig. 2).
- Relative to pre-diagnosis, MBHD increased most in metastatic cancers, especially among younger adults, and changed minimally in older adults with non-metastatic disease (Fig. 3).
- Anxiety was the most frequent MBHD (61%), followed by depression (48%), substance abuse (16%), stress (15%), and somatoform (1%).
- First-onset risk was higher for metastatic vs non-metastatic cancers overall (RR 1.57; 95% CI 1.49–1.65) and across all cancer types, with magnitude varying by type (Fig. 4).
- Any recurrent risk was similar for metastatic vs non-metastatic cancers overall (RR 1.00; 95% CI 0.98–1.03) with minimal variation by cancer type (Fig. 4).
- The relative risk of first-onset MBHD was higher in men than women across both younger and older adults (Fig. 4).

Figure 1. Percent change in MBHD claims status from pre-diagnosis (No, Yes) to post-diagnosis (No, first-onset, new recurrent, existing recurrent) for metastatic vs non-metastatic cancers by age group




Figure 2. Percent of first-onset vs recurrent disorders in patients experiencing MBHD by age group and sex




Figure 3. Percentage point change in MBHD after cancer diagnosis for patients with metastatic vs non-metastatic cancers by age group and sex





Figure 4. Relative risk of first-onset and any recurrent MBHD in metastatic vs non-metastatic cancer patients by cancer type, age group, and sex (95% CI)



CONCLUSIONS

- The increased risk of first-onset MBHDs following metastatic cancer diagnoses relative to earlier diagnoses highlights the burden of late-stage cancer on quality of life.

LIMITATIONS

- This analysis is limited to claims data in a single year and only explored five MBHD.
- Full stage at diagnosis information was not available and metastatic status was inferred from the claims.

METHODS

- A retrospective claims analysis was conducted using the IQVIA PharMetrics Plus dataset for patients newly diagnosed with metastatic and non-metastatic cancers in 2022.
- Enrollees with cancer were identified using ICD-10-CM codes, requiring either one inpatient or two outpatient cancer claims at least 30 days apart.
- Metastatic cancers were identified using the presence of either a claim for a secondary cancer or cancers at two anatomic locations at initial diagnosis.
- Cancer was classified as a new incidence if there was no record of cancer in the preceding year.
- This study only focused on five key cancer related MBHD: anxiety, depression, stress, substance abuse, and somatoform disorders.
 - ICD-10-CM codes: F10-F16, F18-F19; F32-F33; F40-F41; F43-45
- We examined the prevalence of MBHD claims within six months following cancer diagnosis.

- Our analysis distinguished between first-onset and recurrent MBHDs by reviewing claims data one year prior to cancer diagnosis.
 - **First Onset:** Diagnosis of MBHD in the follow-up period without any diagnosis of MBHD in the baseline period
 - **Any Recurrent:** Diagnosis of MBHD in both the follow-up and baseline periods
 - **New Recurrent:** Diagnosis of a specific MBHD in the follow-up period which was not present among any baseline MBHD
 - **Existing Recurrent:** Diagnosis of the same MBHD in both follow-up and baseline periods
- Outcomes were stratified by cancer type, sex, and age group (50-64 and 65+ years).

References: 1. Mitchell AJ, Chan M, Bhatti H et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. *Lancet Oncol* 2011; 12: 160–174. 2. Mausbach BT, Irwin SA. Depression and healthcare service utilization in patients with cancer. *Psycho-Oncology*. 2017. 3. Zhu J, Fang F, Sjölander A, Fall K, Adami H-O, Valdimarsdóttir U. First-onset mental disorders after cancer diagnosis and cancer-specific mortality: a nationwide cohort study. *Ann Oncol*. 2017;28(8):1964–1969.

Disclosures: Study funded by GRAIL, Inc. Ali Tafazzoli and Anuraag Kansal are employees of GRAIL, Inc. and may have equity in the company. Yi Zhang and Yen-Hua Chen are employees of KMK Consulting, which received financial support from GRAIL for work on this study.